CelLBxHealth plc · LSE:CLBX
CelLBxHealth — ANGLE — H1 2012 Earnings Presentation
12 slides from CelLBxHealth's earnings presentation, Jan 26, 2012
Slide 1: Interim Results Presentation
Interim Results Presentation For the six months ended 31 October 2011 Presented by: Andrew Newland, Chief Executive Officer Ian Griffiths, Finance Director 26 January 2012
Slide 2: Legal disclaimer
Legal disclaimer The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment (without notice), verification and completeness. This document is directed at investment professionals as defined in Article 19(5) of the Financial Services an
Slide 3: Operational Highlights
Operational Highlights Parsortix Cancer Diagnostics • Holding increased to 90% • Technology successfully used to capture cultured cancer cells added to healthy blood (spiked blood) and product development programme initiated for a cancer diagnostic device • Successfully captured cultured breast, pro
Slide 4: Financial Results for the six months ended 31 October 2011
Financial Results for the six months ended 31 October 2011 CONTINUING OPERATIONS H1 2012 H1 2011 Statement of comprehensive income £’000 £’000 Comments Turnover 703 1,363 Investments portfolio (loss) / gain (1,346) 175 Planned increase in spend on controlled investments, primarily Parsortix Manageme
Slide 5: Update on Novocellus: IVF embryo viability
Update on Novocellus: IVF embryo viability As announced today • Novocellus has a partnership with ORIGIO, a leading supplier of specialised IVF products • New improved development terms agreed between Novocellus and ORIGIO to kick start trials and accelerate timescales • ANGLE will contribute to cer
Slide 6: Parsortix: cancer diagnostics
Parsortix: cancer diagnostics separation cassette schematic Cassette components Fully assembled cassette Cassette housing © ANGLE plc 2012 Page 6
Slide 7: Captured cells: whole blood control and spiked with SK-Br-3
Captured cells: whole blood control and spiked with SK-Br-3 Control Spiked with breast cancer cells © ANGLE plc 2012 Page 7
Slide 8: Chromogenic staining of SK-Br-3 cells
Chromogenic staining of SK-Br-3 cells Stained breast Cancer cells Visual ID breast cancer cells Identified cells marked using cytokeratin-18 © ANGLE plc 2012
Slide 9: Parsortix Update
Parsortix Update Announced this week • Achieved major milestone by using Parsortix cell separation device to successfully capture CTCs in cancer patient blood • This is significant as actual cancer patient blood would be expected to contain only a very small number of CTCs in the sample as well as p
Slide 10: Key Milestones for Parsortix for 2012
Key Milestones for Parsortix for 2012 • Finalise work on characterising the separation device including flow and volume capability • Finalise market requirements for device • Optimise design of separation device (next generation) • Establish further collaborations with cancer research centres • Beta
Slide 11: Investment Summary
Investment Summary • ANGLE’s three major investments offer potential for substantial returns • Parsortix and Novocellus targeting highly attractive markets • Geomerics providing near term revenue generation • Diversification = risk protection • Further value enhancing milestones to be achieved over
Slide 12: Contact details
Contact details Andrew Newland Chief Executive ANGLE plc 3 Frederick Sanger Road The Surrey Research Park Guildford GU2 7YD United Kingdom Tel: +44 1483 685830 Fax: +44 1483 685836 Email: andrew.newland@ANGLEplc.com Website: www.ANGLEplc.com © ANGLE plc 2012 Page 12